Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 05, 2020 16:01 ET | Source: Zogenix, Inc

Zogenix Provides Corporate Update and Reports First Quarter 2020 Financial Results

FDA PDUFA target action date of June 25, 2020, for FINTEPLA® NDA in Dravet syndromePlan to meet with FDA in second half of 2020 to discuss planned FINTEPLA Lennox-Gastaut syndrome sNDAClosed public...
April 28, 2020 08:00 ET | Source: Zogenix, Inc

Zogenix to Release First Quarter 2020 Financial Results and Host Conference Call and Webcast on May 5

EMERYVILLE, Calif., April 28, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will report its...
April 20, 2020 08:00 ET | Source: Zogenix, Inc

Zogenix Appoints Shawnte Mitchell as Executive Vice President, General Counsel & Secretary

EMERYVILLE, Calif., April 20, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced it has appointed Shawnte M....
April 15, 2020 08:00 ET | Source: Zogenix, Inc

Zogenix to Host Investor Conference Call and Webcast on Two Studies Evaluating FINTEPLA® in Dravet Syndrome and Sunflower Syndrome

EMERYVILLE, Calif., April 15, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX), a global pharmaceutical company developing rare disease therapies, announced today that it will host an investor...
March 06, 2020 16:05 ET | Source: Zogenix, Inc

Zogenix Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

EMERYVILLE, Calif., March 06, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX), a global pharmaceutical company developing rare disease therapies, announced today that it has closed its...
March 03, 2020 21:05 ET | Source: Zogenix, Inc

Zogenix Prices Public Offering of Common Stock

EMERYVILLE, Calif., March 03, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX), a global pharmaceutical company developing rare disease therapies, announced today that it has priced an...
March 03, 2020 17:07 ET | Source: Zogenix, Inc

Zogenix Announces Proposed Public Offering of Common Stock

EMERYVILLE, Calif., March 03, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX), a global pharmaceutical company developing rare disease therapies, announced today that it intends to offer and...
March 02, 2020 16:01 ET | Source: Zogenix, Inc

Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2019 Financial Results

NDA for FINTEPLA® in Dravet syndrome accepted for review by FDA; new PDUFA target acion date of June 25, 2020Two-year interim analysis of FINTEPLA open-label extension study in Dravet syndrome...
February 27, 2020 08:00 ET | Source: Zogenix, Inc

Zogenix Announces FDA Extension of Review Period for FINTEPLA® in Dravet Syndrome

EMERYVILLE, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that the U.S. Food and Drug...
February 24, 2020 08:00 ET | Source: Zogenix, Inc

Zogenix to Release Fourth Quarter and Full-Year 2019 Financial Results and Host Conference Call and Webcast on March 2

EMERYVILLE, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will report its...